Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
Autorzy:
Hobbs FDR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.; NIHR Applied Research Collaboration (ARC) Oxford Thames Valley, Oxford, UK. Montgomery H; Department of Medicine, University College London, London, UK. Padilla F; Centro de Investigación en Cardiología y Metabolismo, Guadalajara, Jalisco, Mexico. Simón-Campos JA; Köhler and Milstein Research/Méchnikov Project, Universidad Autonoma de Yucatan, Mérida, Yucatán, Mexico. Arbetter D; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA. Seegobin S; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Kiazand A; Patient Safety, Chief Medical Office, R&D and Vaccines and Immune Therapies, AstraZeneca, Gaithersburg, MD, USA. Streicher K; Vaccines and Immune Therapies, BioPharmaceuticals R&D, Astrazeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. Martinez-Alier N; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Cohen TS; Vaccines and Immune Therapies, BioPharmaceuticals R&D, Astrazeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. EsserMT; Vaccines and Immune Therapies, BioPharmaceuticals R&D, Astrazeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. mark.esser@astrazeneca.com.
Pokaż więcej
Źródło:
Infectious diseases and therapy [Infect Dis Ther] 2024 Mar; Vol. 13 (3), pp. 521-533. Date of Electronic Publication: 2024 Feb 25.
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Autorzy:
Hobbs FDR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Montgomery H; Department of Medicine, University College London, London, UK. Padilla F; Centro de Investigación en Cardiología y Metabolismo, Guadalajara, Jalisco, Mexico. Simón-Campos JA; Köhler & Milstein Research/Méchnikof Project, Mérida, Yucatán, Mexico. Kim K; ARK Clinical Research, Long Beach, CA, USA. Arbetter D; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA. Padilla KW; Clinical Development, Late-Stage Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA. Reddy VP; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Seegobin S; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Streicher K; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Templeton A; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Viani RM; Late-Stage Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Johnsson E; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Koh GCKW; Clinical Development, Late-Stage Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. EsserMT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 20878, USA. mark.esser@astrazeneca.com.
Pokaż więcej
Źródło:
Infectious diseases and therapy [Infect Dis Ther] 2023 Sep; Vol. 12 (9), pp. 2269-2287. Date of Electronic Publication: 2023 Sep 26.
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS-CoV-2 infection or vaccination.
Autorzy:
Wilkins D; Translational Medicine, Vaccines and Immune Therapies BioPharmaceuticals Medical AstraZeneca Gaithersburg MD USA. Aksyuk AA; Translational Medicine, Vaccines and Immune Therapies BioPharmaceuticals Medical AstraZeneca Gaithersburg MD USA. Ruzin A; Translational Medicine, Vaccines and Immune Therapies BioPharmaceuticals Medical AstraZeneca Gaithersburg MD USA. Tuffy KM; Translational Medicine, Vaccines and Immune Therapies BioPharmaceuticals Medical AstraZeneca Gaithersburg MD USA. Green T; PPD® Laboratories Vaccine Sciences Lab Richmond VA USA. Greway R; PPD® Laboratories Vaccine Sciences Lab Richmond VA USA. Fikes B; PPD® Laboratories Vaccine Sciences Lab Richmond VA USA. Bonhomme CJ; PPD® Laboratories Vaccine Sciences Lab Richmond VA USA. EsserMT; Translational Medicine, Vaccines and Immune Therapies BioPharmaceuticals Medical AstraZeneca Gaithersburg MD USA. Kelly EJ; Translational Medicine, Vaccines and Immune Therapies BioPharmaceuticals Medical AstraZeneca Gaithersburg MD USA.
Pokaż więcej
Źródło:
Clinical & translational immunology [Clin Transl Immunology] 2022 Apr 26; Vol. 11 (4), pp. e1385. Date of Electronic Publication: 2022 Apr 26 (Print Publication: 2022).
Evaluation of GeneXpert PA assay compared to genomic and (semi-)quantitative culture methods for direct detection of Pseudomonas aeruginosa in endotracheal aspirates.
Autorzy:
van der Schalk TE; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium. Coppens J; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium.; Laboratory of Clinical Microbiology, Antwerp University Hospital , Edegem, Belgium. Timbermont L; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium. Turlej-Rogacka A; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium. Van Heirstraeten L; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium. Berkell M; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium. Yu L; Statistical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. Lammens C; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium. Xavier BB; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium. Matheeussen V; Laboratory of Clinical Microbiology, Antwerp University Hospital , Edegem, Belgium. Ieven M; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium.; Laboratory of Clinical Microbiology, Antwerp University Hospital , Edegem, Belgium. McCarthy M; Early-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. Jorens PG; Department of Intensive Care Medicine , Antwerp University Hospital , Edegem , Belgium. Ruzin A; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. EsserMT; Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. Kumar-Singh S; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium.; Molecular Pathology Group, Cell Biology and Histology, University of Antwerp, Wilrijk, Belgium. Goossens H; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium.; Laboratory of Clinical Microbiology, Antwerp University Hospital , Edegem, Belgium. Malhotra-Kumar S; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute , University of Antwerp, Wilrijk, Belgium. .
Characterization of human respiratory syncytial virus (RSV) isolated from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during 2015-2017.
Autorzy:
Liu H; AstraZeneca, South San Francisco, CA, USA. Lu B; AstraZeneca, South San Francisco, CA, USA. Tabor DE; AstraZeneca, South San Francisco, CA, USA. Tovchigrechko A; AstraZeneca, Gaithersburg, MD, USA. Wilkins D; AstraZeneca, Gaithersburg, MD, USA. Jin H; AstraZeneca, South San Francisco, CA, USA. Madhi SA; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Soofie N; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. EsserMT; AstraZeneca, Gaithersburg, MD, USA. Nunes MC; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort.
Autorzy:
Bouquet J; Clinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, South San Francisco, USA. . Tabor DE; Clinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, South San Francisco, USA. Silver JS; Respiratory Inflammation and Autoimmunity, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. Nair V; Clinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, South San Francisco, USA. Tovchigrechko A; Data Science and AI, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. Griffin MP; Respiratory Inflammation and Autoimmunity, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. EsserMT; Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. Sellman BR; Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA. Jin H; Clinical Pharmacology & Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, South San Francisco, USA.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2020 Mar 30; Vol. 21 (1), pp. 77. Date of Electronic Publication: 2020 Mar 30.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study
Associations of pathogen-specific and host-specific characteristics with disease outcome in patients with Staphylococcus aureus bacteremic pneumonia.
Autorzy:
Sharma-Kuinkel BK; Division of Infectious Diseases, Department of Medicine, Duke University Durham NC USA. Tkaczyk C; Microbial Sciences, AstraZeneca Gaithersburg MD USA. Bonnell J; Microbial Sciences, AstraZeneca Gaithersburg MD USA. Yu L; Statistical Sciences, AstraZeneca Gaithersburg MD USA. Tovchigrechko A; Data Science & Artificial Intelligence, AstraZeneca Gaithersburg MD USA. Tabor DE; Microbial Sciences, AstraZeneca Gaithersburg MD USA. Park LP; Division of Infectious Diseases, Department of Medicine, Duke University Durham NC USA. Ruffin F; Division of Infectious Diseases, Department of Medicine, Duke University Durham NC USA. EsserMT; Microbial Sciences, AstraZeneca Gaithersburg MD USA. Sellman BR; Microbial Sciences, AstraZeneca Gaithersburg MD USA. Fowler VG Jr; Division of Infectious Diseases, Department of Medicine, Duke University Durham NC USA. Ruzin A; Microbial Sciences, AstraZeneca Gaithersburg MD USA.
Pokaż więcej
Źródło:
Clinical & translational immunology [Clin Transl Immunology] 2019 Jul 19; Vol. 8 (7), pp. e01070. Date of Electronic Publication: 2019 Jul 19 (Print Publication: 2019).
Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States.
Autorzy:
Ruzin A; AstraZeneca/MedImmune, Gaithersburg, Maryland, United States of America. Pastula ST; Epidstat Institute, Ann Arbor, Michigan, United States of America. Levin-Sparenberg E; Epidstat Institute, Ann Arbor, Michigan, United States of America. Jiang X; Epidstat Institute, Ann Arbor, Michigan, United States of America. Fryzek J; Epidstat Institute, Ann Arbor, Michigan, United States of America. Tovchigrechko A; AstraZeneca/MedImmune, Gaithersburg, Maryland, United States of America. Lu B; AstraZeneca/MedImmune, Mountain View, California, United States of America. Qi Y; AstraZeneca/MedImmune, Mountain View, California, United States of America. Liu H; AstraZeneca/MedImmune, Mountain View, California, United States of America. Jin H; AstraZeneca/MedImmune, Mountain View, California, United States of America. Yu L; AstraZeneca/MedImmune, Gaithersburg, Maryland, United States of America. Hackett J; AstraZeneca/MedImmune, Gaithersburg, Maryland, United States of America. Villafana T; AstraZeneca/MedImmune, Gaithersburg, Maryland, United States of America. EsserMT; AstraZeneca/MedImmune, Gaithersburg, Maryland, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2018 Jul 24; Vol. 13 (7), pp. e0200319. Date of Electronic Publication: 2018 Jul 24 (Print Publication: 2018).
Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus.
Autorzy:
Maifeld SV; Applied Immunology and Microbiology, MedImmune, Mountain View, California, United States of America. Ro B; Applied Immunology and Microbiology, MedImmune, Mountain View, California, United States of America. Mok H; Applied Immunology and Microbiology, MedImmune, Mountain View, California, United States of America. Chu M; Applied Immunology and Microbiology, MedImmune, Mountain View, California, United States of America. Yu L; Non-clinical Biostatistics, MedImmune, Gaithersburg, Maryland, United States of America. Yamagata R; Non-clinical Biostatistics, MedImmune, Gaithersburg, Maryland, United States of America. Leonardson T; Vaccine and Analytical Sciences, MedImmune, Mountain View, California, United States of America. Chio V; Vaccine and Analytical Sciences, MedImmune, Mountain View, California, United States of America. Parhy B; Applied Immunology and Microbiology, MedImmune, Mountain View, California, United States of America. Park S; Vaccine and Analytical Sciences, MedImmune, Mountain View, California, United States of America. Carlson M; Purification Process Sciences, MedImmune, Gaithersburg, Maryland, United States of America. Machhi S; Cell Culture and Fermentation Sciences, MedImmune, Gaithersburg, Maryland, United States of America. Ulbrandt N; Department of Infectious Disease and Vaccines, Gaithersburg, California, United States of America. Falsey AR; Department of Medicine, University of Rochester School of Medicine and Dentistry, and Department of Medicine, Rochester General Hospital, Rochester, New York, United States of America. Walsh EE; Department of Medicine, University of Rochester School of Medicine and Dentistry, and Department of Medicine, Rochester General Hospital, Rochester, New York, United States of America. Wang CK; Applied Immunology and Microbiology, MedImmune, Mountain View, California, United States of America. EsserMT; Translational Medicine, MedImmune, Gaithersburg, Maryland, United States of America. Zuo F; Applied Immunology and Microbiology, MedImmune, Mountain View, California, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Apr 12; Vol. 11 (4), pp. e0153019. Date of Electronic Publication: 2016 Apr 12 (Print Publication: 2016).
Typ publikacji:
Evaluation Study; Journal Article; Research Support, N.I.H., Extramural
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
